Source: Virtual Congress 2021 – Therapy of lung cancer



Rating:

Share or cite this content

Citations should be made in the following way:
A. Charpidou (Athens, Greece), V. Patriarcheas (Athens, Greece), I. Vathiotis (Athens, Greece), E. Kokotou (Athens, Greece), N. Syrigos (Athens, Greece), M. Mani (Athens, Greece), L. Stournara (Athens, Greece), I. Gkiozos (Athens, Greece). Immune-related adverse events as a predictor marker of response to programmed cell death 1/programmed death-ligand 1 axis inhibitors in patients with non-small cell lung cancer.. 2305

Member's Comments

No comment yet.

Related content which might interest you: The expression of central cell cycle regulators in non-small cell lung cancer has therapy-dependent prognostic impact Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Relationship between Cancer-associated fibroblast and programmed death ligand 1 expression in non-small cell lung cancer Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 IRP2 as a potential modulator of cell proliferation, apoptosis and prognosis in nonsmall cell lung cancer Source: Eur Respir J , 49 (4)  1600711; DOI: 10.1183/13993003.00711-2016 Year: 2017 The death receptor Fas in CD3+T cells in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 673s Year: 2004 Magnolol can induce apoptosis in non-small cell lung cancer via caspase-independent pathway Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer Year: 2011 Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006 KPNB1-mediated PD-L1 nuclear translocation promotes non-small cell lung cancer cell proliferation via the Gas6/MerTK signalling pathway Source: Virtual Congress 2020 – Biological mechanisms of lung cancer Year: 2020 Specific plasmids encoding shRNA molecules directed against growth factor receptors in cell proliferation inhibition and induction phenotype changes relevant to enhancement of anti-tumor immunity. Model of human non-small (NSCLC) and small (SCLC) cell lung cancer lines Source: Annual Congress 2010 - Pathology of lung cancer Year: 2010 Adaptation to hypoxia leads to apoptosis resistance to cisplatin in non-small cell lung cancer (NSCLC) cell line Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology Year: 2008 Polymorphisms in mitotic checkpoint-related genes can influence survival outcomes of early-stage non-small cell lung cancer Source: International Congress 2017 – Clinical research in lung cancer: new valuable results on lung cancer detection, prognostic biomarkers, and tyrosine kinase inhibitors Year: 2017 HIF-1α modulation by topoisomerase inhibitors in A549, a non-small cell lung cancer cell line Source: Annual Congress 2007 - Biology in thoracic oncology Year: 2007 Predictors of response to ZD1839 (IressaÔ) in refractory non-small cell lung cancer Source: Annual Congress 2004 - Management of lung cancer and innovative therapies Year: 2004 Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs Year: 2008 A low endothelial cell proliferation fraction, a measurement of ongoing angiogenesis, is associated with poor prognosis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 763s Year: 2006 Differences in growth signaling pathway activation in small cell and non-small cell carcinomas of the lung Source: Eur Respir J 2006; 28: Suppl. 50, 326s Year: 2006 The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007 PD-L1 is a potential negative prognostic factor for non-small cell lung cancer: A 5-year-follow-up study Source: Annual Congress 2011 - Progress in pathology of lung cancer Year: 2011 CHD4 is associated with poor prognosis of non-small cell lung cancer patients through promoting tumor cell proliferation Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Lower APCR correlates with apoptotic activation of CD8+T cells in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 356s Year: 2004 Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer Source: Eur Respir Rev, 28 (153) 190058; 10.1183/16000617.0058-2019 Year: 2019